Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Exclusive: Amgen's new leukemia drug to carry $178,000 price tag

Published 12/17/2014, 11:52 AM
Updated 12/17/2014, 11:52 AM
© Reuters. An Amgen sign is seen at the company's office in South San Francisco

© Reuters. An Amgen sign is seen at the company's office in South San Francisco

By Ransdell Pierson

(Reuters) - Amgen Inc on Wednesday said its new type of treatment for a deadly form of leukemia would cost about $178,000 when it becomes available on Thursday, which would make it one of the world's most expensive cancer drugs.

Company spokeswoman Danielle Bertrand said the price for the infused medicine, called Blincyto, would reflect two courses of treatment, at $89,000 per cycle.

"We believe the price reflects the significant clinical, economic and humanistic value of the product to patients and the healthcare system, for an ultra-orphan population with a dramatic impact on a serious illness," Amgen said in an emailed statement.

The world's largest biotech company also said the price reflects the complexity of developing and making innovative biotech drugs.

U.S. regulators on Dec. 3 approved the Amgen drug more than five months ahead of the expected decision date, to treat a blood cancer called acute lyphoblastic leukemia (ALL), for which there are few options once a patient has relapsed following standard treatment.

The initial approval is for patients whose cancer has returned after treatment or did not respond to previous treatment, such as a stem cell transplant or chemotherapy.

In a clinical trial used for the approval decision, 32 percent of patients achieved complete remission for nearly seven months after receiving the drug via infusion for four weeks.

An estimated 6,020 Americans in 2014, almost half of them children, will be diagnosed with ALL and 1,440 will die from the disease, according to the National Cancer Institute. It is the most common form of leukemia affecting children.

Amgen acquired Blincyto through its $1.2 billion purchase in 2012 of Micromet, a biotechnology company founded in Germany. At the time, Blincyto was known by its chemical name, blinatumomab.

The drug is a so-called bispecific antibody, a hot emerging technology that could prove more potent than conventional antibodies, which have become mainstay treatments for a wide array of cancers.

Antibodies are proteins that look out for "foreign" invaders such as bacteria, as well as for aberrant fast-growing cells like cancer. The Y-shaped proteins have two arms that bind the same protein target found on cancer cells, in an attempt to neutralize the cells.

With bispecific antibodies, however, one arm grasps the cancer cell, while the other takes hold of an immune system defender called a T cell, bringing the enemies into contact and leading to destruction of the cancer cell.

Immuno-oncology drugs, which stimulate the immune system or prevent tumor cells from hiding themselves, have become a main focus of drugmakers, following approval in 2011 of Bristol-Myers Squibb Co's Yervoy treatment for melanoma. It costs about $120,000 for a complete course of four infusions.

© Reuters. An Amgen sign is seen at the company's office in South San Francisco

Yervoy and members of another class of drugs called PD-1 inhibitors, including Merck & Co's recently approved Keytruda, work by removing a brake on the immune system. Keytruda costs about $150,000 for a year of treatment.

(Reporting by Ransdell Pierson; Editing by Lisa Von Ahn and David Gregorio)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.